7.3.3	  Summary of evidence and recommendations for the treatment of metastatic UTUC,
Recommendations  Strength rating,
First-line treatment for platinum-eligible patients,
Offer platinum combination chemotherapy to platinum-eligible patients.,Strong
Offer cisplatin-based chemotherapy with gemcitabine/cisplatin or HD-MVAC to cisplatin-  eligible patients.,Strong
Offer maintenance avelumab to patients who did not have disease progression after 4 to    6 cycles of gemcitabine plus cisplatin/carboplatin.,Strong
First-line treatment in patients ineligible for cisplatin or carboplatin,
Offer gemcitabine/carboplatin chemotherapy to cisplatin-ineligible patients.  Strong,
Offer checkpoint inhibitors pembrolizumab or atezolizumab to patients with PD-L1 positive   Weak  tumours.,
Second-line treatment,
Offer checkpoint inhibitor (pembrolizumab) to patients with disease progression during or   after platinum-based combination chemotherapy for metastatic disease.,Strong
Offer enfortumab vedotin to patients previously treated with platinum-containing   chemotherapy and who had disease progression during or after treatment with a PD-1 or   PD-L1 inhibitor.,Strong
